ISAL 2023 | Personalizing therapy in AML: current status and future outlooks
Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY, shares some insights into the importance of personalizing therapy for patients with acute myeloid leukemia (AML) and approaches being explored. For younger patients, intensive chemotherapy and transplant remains the backbone of therapy, whereas the older population requires more personalized approaches. Prof. Konopleva highlights options for patients with various mutational profiles, including FLT3 mutation, IDH mutation, and TP53 mutation, and concludes by commenting on the importance of exploring other options for patients who are not fit enough to tolerate azacitidine-venetoclax. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting: AbbVie, Forty Seven, Daiichi, Precision Biosciences, Gilead, Genentech, Janssen, Sanofi, AstraZeneca, MEI Pharma, Menarini-Stemline Therapeutics,
Research Funding: AbbVie, Allogene, Cellectis, Forty Seven, Daiichi, Precision Biosciences, Gilead, Genentech, Sanofi, AstraZeneca, MEI Pharma, Menarini-Stemline Therapeutics, Rafael Pharmaceutical
Advisory board: AbbVie, Genentech, Janssen, Menarini-Stemline Therapeutics
Clinical trials support: AbbVie, Cellectis, Forty Seven, Genentech, AstraZeneca, Menarini-Stemline Therapeutics
Stockholder: Reata Pharmaceutical
Royalty: Reata Pharmaceutical
